TECH · Bio-Techne Corp

The thesis

Bio-Techne's shares trade as a proxy for Merck KGaA's $73.00-per-share cash offer. Shareholders approved the merger on 23 September 2026, so what settles the case now is receipt of the remaining regulatory approvals and payment, which the company expects toward the end of 2026 or in early 2027.

The adjusted daily close was $72.69 on 28 October 2026, equal to the 52-week high. The cash price caps the gain, so the shares have little room to outperform the S&P 500 over three months unless a competing proposal appears. A daily close below $70 would show the market doubting payment.

The narrative is saturated: analyst downgrades clustered between 29 June 2026 and 9 July 2026, and the 23 September 2026 vote removed the last scheduled event. A search of trade-press coverage on 29 October 2026 found no announcement of a final approval or a closing date since the vote.

Bullish and bearish views on Bio-Techne Corp

The bull case on Bio-Techne Corp (TECH), in brief: Shareholders approved the merger. The bear case: Some regulatory approvals are still open.

Bull case

• Shareholders approved the merger. Bio-Techne's 23 September 2026 press release says holders voted to approve and adopt the merger agreement. The release gave no vote tally.
• The US antitrust waiting period has expired. The Hart-Scott-Rodino waiting period ended at 11:59 p.m. Eastern time on 18 September 2026, per the same release. Germany's Federal Cartel Office had already cleared the deal in its first-phase review.
• The injunction suit did not stop the vote. A lawsuit filed 9 September 2026 sought to enjoin the meeting, per Bio-Techne's 8-K dated 14 September 2026. The meeting was held on 23 September 2026 as scheduled.
• Merck KGaA carries the larger break fee. The merger agreement disclosed 26 June 2026 sets a $576.1M reverse termination fee payable by Merck KGaA, against $230.5M payable by Bio-Techne.

Bear case

• Some regulatory approvals are still open. Bio-Techne's 23 September 2026 release refers to "remaining required regulatory approvals" without naming them. Press coverage on that date lists clearances in several other jurisdictions as still pending.
• The payoff is capped and timing is open. Bio-Techne guides to a close toward the end of 2026 or in early 2027. The merger agreement's outside date is 25 March 2027, so a delay stretches the wait for the $73.00 payment.
• Little visibility between filings. Bio-Techne holds no quarterly investor calls and gave no FY27 guidance while the deal is pending, per its 12 August 2026 Q4 release.
• A new analyst downgrade to Sell. Argus cut Bio-Techne to Sell from Buy on 27 October 2026, per a company news feed headline that gave no target or reason. With the shares near the offer price, the view that further upside is limited fits the capped payoff, though Argus has not said that was its reason.

Price setup

The adjusted daily close on 28 October 2026 was $72.69, a new 52-week high and just under the $73.00 offer. The shares rose 0.9% over three months. The 14-day relative strength index (RSI) read 63.0.

The price is tied to a fixed cash offer, so these readings describe a security sitting just under its payout and carry little independent information. The level that matters is $70: a daily close below it would mean the market is pricing a real chance that the deal fails or is badly delayed.

Crowding evidence is thin. The analyst downgrades in late June and early July came with targets set at $73, and no insider selling or share issuance appears in recent filings.

Catalysts, next 30 days

No dated event inside the next 30 days is confirmed. The shareholder vote (23 September 2026) and the US antitrust expiry (18 September 2026) are behind the deal, and no further approval has a published date.

• ~31 December 2026, est.: the company-guided closing window begins. Remaining approvals decide the payment date.
• 25 March 2027: merger agreement outside date. Either party could terminate if approvals are missing and no extension is invoked.

An announcement of a final regulatory clearance or a closing date could arrive at any time, and either would narrow the gap to $73.00.

What would change the view

The case breaks if a regulator prohibits the deal, if Merck KGaA or Bio-Techne issues a termination notice, or if a disclosed in-depth review pushes expected closing past the 25 March 2027 outside date. Any of these would remove or defer the $73.00 payment.

On price, a daily close below $70 would show the market doubting payment. A competing proposal above $73.00 would change the capped-upside reading, though none has been reported.

What it trades with

The shares follow the deal's completion odds and Merck KGaA's credit and financing, not the life-science tools sector or the broader market. Bio-Techne's price should move little with sector earnings while the offer stands.

Sector takeover news, such as the 10 July 2026 report of private equity interest in Qiagen, does not change the terms of this offer. Deal-specific news and regulatory announcements are the main drivers.